Genetic deletion of A2AR in host animals favors rejection of immunogenic tumors and anti-cancer immunity is restored only upon administration of A2AR antagonists, or by silencing the receptor via siRNA pretreatment on T-cells (Ohta et al., 2006). Here, ADORA2A is linked to cancer.